Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Clinical evidence

MARIPOSA

60 evidence topics · 6 sources

Objective
Location and study date
Registry dates
FieldRegistry entry
Study start (actual)“2021-11-29”
Primary completion (actual)“2022-07-20”
Study completion (actual)“2022-08-03”
Study design
Eligibility criteria
Inclusion and exclusion criteria in the publication (AHI4 of 10 to 45 by two polysomnograms)

“Participants were adults with OSA with a mean apnea–hypopnea index using the ⩾4% desaturation criterion for hypopneas (AHI4) of 10–45 based on two screening/baseline polysomnography (PSG) studies, with <25% of events comprising central or mixed apnea.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Age requirement was 18–65 years for men and 18–75 for women. Body mass index was required to be ⩽38 kg/m2 for men and ⩽40 kg/m2 for women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Key exclusion criteria were clinically important sleep disorders other than OSA, active cardiac diseases (rhythm disturbance, coronary artery disease, or heart failure), hypertension requiring more than two drugs for control, craniofacial malformation or grade ⩾3 tonsillar hypertrophy, work schedule involving night or shift work, and chronic therapy with monoamine oxidase inhibitors, norepinephrine reuptake inhibitors, α-1 antagonists, tricyclic antidepressants, strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, duloxetine), opioids, muscle relaxants, wake-promoting agents, antipsychotic agents, anticholinergic agents, or warfarin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants treated with CPAP, oral or nasal devices, or positional devices could enroll as long as the devices had not been used for ⩾2 weeks before the first PSG study and were not used during participation in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Treatment
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registry enrollment of 294 participants, including the AD504 arms
Description of analysis sets
Results
Participant disposition
Registry participant flow, all arms including AD504
MilestoneAD109 75/5mgAD109 75/2.5mgAD504 75/100mgAD504 75/50mgAtomoxetine 75mgPlacebo
Started“41”“42”“43”“40”“64”“64”
Completed“35”“33”“38”“38”“49”“59”
Not completed“6”“9”“5”“2”“15”“5”
Withdrawn due to adverse event“5”“5”“3”“1”“12”“1”
Baseline characteristics
Demographic and clinical characteristics of the safety population
CharacteristicPlacebo (n = 63)Atomoxetine 75 mg (n = 63)AD109 2.5/75 mg (n = 42)AD109 5/75 mg (n = 41)
Age, years, median (IQR)“57 (48–62)”View highlighted excerpt for this quote“56 (49–60)”View highlighted excerpt for this quote“53.5 (44–58)”View highlighted excerpt for this quote“55 (49–60)”View highlighted excerpt for this quote
Female sex“27 (42.9%)”View highlighted excerpt for this quote“22 (34.9%)”View highlighted excerpt for this quote“17 (40.5%)”View highlighted excerpt for this quote“19 (46.3%)”View highlighted excerpt for this quote
BMI, kg/m2, median (IQR)“32.0 (27.2–35.2)”View highlighted excerpt for this quote“31.2 (28.11–34.6)”View highlighted excerpt for this quote“34.5 (31.6–36.6)”View highlighted excerpt for this quote“31.2 (27.5–34.0)”View highlighted excerpt for this quote
CPAP use“29 (46.1%)”View highlighted excerpt for this quote“30 (47.6%)”View highlighted excerpt for this quote“18 (42.9%)”View highlighted excerpt for this quote“21 (50.2%)”View highlighted excerpt for this quote
Black or African American“9 (14.3%)”View highlighted excerpt for this quote“5 (7.9%)”View highlighted excerpt for this quote“11 (26.2%)”View highlighted excerpt for this quote“6 (14.6%)”View highlighted excerpt for this quote
White“48 (76.2%)”View highlighted excerpt for this quote“52 (82.5%)”View highlighted excerpt for this quote“28 (66.7%)”View highlighted excerpt for this quote“33 (80.5%)”View highlighted excerpt for this quote
Hypertension“14 (22%)”View highlighted excerpt for this quote“8 (13%)”View highlighted excerpt for this quote“6 (14%)”View highlighted excerpt for this quote“12 (29%)”View highlighted excerpt for this quote
Diabetes“1 (2%)”View highlighted excerpt for this quote“8 (13%)”View highlighted excerpt for this quote“3 (7%)”View highlighted excerpt for this quote“4 (10%)”View highlighted excerpt for this quote
Registry baseline age and body mass index, safety set of all arms
CharacteristicAD109 75/5mgAD109 75/2.5mgAtomoxetine 75mgPlaceboTotal (all six arms)
Participants“41”“42”“63”“63”“292”
Age, years, mean (SD)“54.2(9.24)”“51.5(9.22)”“52.8(10.95)”“54.9(9.03)”“54.2(9.49)”
BMI, kg/m2, mean (SD)“31.12(4.085)”“33.43(4.352)”“31.16(4.716)”“31.17(4.719)”“31.65(4.389)”
Efficacy results
Respiratory parameters: AHI4 (4% criterion) in NREM and REM sleep
ArmNREM baselineNREM treatmentNREM placebo-adjusted changeREM baselineREM treatmentREM placebo-adjusted change
Placebo“19.3 (9.4–27.7)”View highlighted excerpt for this quote“16.7 (9.2–27.3)”View highlighted excerpt for this quoteNot applicable“20.9 (9.3–33.9)”View highlighted excerpt for this quote“20.3 (6.1–36.1)”View highlighted excerpt for this quoteNot applicable
Atomoxetine 75 mg“18.4 (9.4–28.6)”View highlighted excerpt for this quote“11.4 (4.4–19.4)”View highlighted excerpt for this quote“−4.22 (−7.81 to −0.63)”View highlighted excerpt for this quote“28.1 (15.7–21.6)”View highlighted excerpt for this quote“18.5 (9.1–26.8)”View highlighted excerpt for this quote“−5.77 (−11.66 to 0.71)”View highlighted excerpt for this quote
AD109 2.5/75 mg“16.0 (9.6–24.7)”View highlighted excerpt for this quote“10.1 (3.5–16.4)”View highlighted excerpt for this quote“−5.38 (−9.41 to −1.34)”View highlighted excerpt for this quote“30.2 (18.1–50.7)”View highlighted excerpt for this quote“18.2 (7.6–43.5)”View highlighted excerpt for this quote“−5.67 (−12.74 to 1.41)”View highlighted excerpt for this quote
AD109 5/75 mg“19.0 (10.1–30.7)”View highlighted excerpt for this quote“8.3 (5.9–19.5)”View highlighted excerpt for this quote“−6.45 (−10.44 to −2.46)”View highlighted excerpt for this quote“22.6 (13.0–34.4)”View highlighted excerpt for this quote“13.8 (6.6–31.8)”View highlighted excerpt for this quote“−3.34 (−10.39 to 3.72)”View highlighted excerpt for this quote
Registry primary outcome: change in AHI4 (4% criterion), combined AD109 arms, mITT
GroupParticipants analyzedLS mean change from baseline (95% CI), events/hr
AD109 combined dose arms“69”“-7.38 (-9.53 to -5.23)”
AD109 75/5mg“35”“-7.40 (-10.41 to -4.38)”
AD109 75/2.5mg“34”“-7.37 (-10.44 to -4.30)”
Placebo“62”“-0.21 (-2.49 to 2.07)”
Sleep architecture: total sleep time, REM sleep, and wake after sleep onset
Parameter and armBaseline, median (IQR)Treatment, median (IQR)Placebo-adjusted change, LS mean (95% CI)
TST, min: placebo“386.4 (362.3–428.0)”View highlighted excerpt for this quote“399.4 (358.5–426.5)”View highlighted excerpt for this quoteNot applicable
TST, min: atomoxetine 75 mg“396.4 (364.0–427.0)”View highlighted excerpt for this quote“372.2 (340.5–406.0)”View highlighted excerpt for this quote“−21.46 (−34.3 to −8.59)”View highlighted excerpt for this quote
TST, min: AD109 2.5/75 mg“387.5 (352.8–412.9)”View highlighted excerpt for this quote“385.5 (364.8–416.5)”View highlighted excerpt for this quote“2.48 (−12.01 to 16.96)”View highlighted excerpt for this quote
TST, min: AD109 5/75 mg“387.9 (360.9–425.8)”View highlighted excerpt for this quote“392.6 (355.5–421.8)”View highlighted excerpt for this quote“−5.37 (−19.65 to 8.91)”View highlighted excerpt for this quote
REM sleep, %TST: placebo“17.9 (14.7–20.1)”View highlighted excerpt for this quote“17.2 (13.6–20.8)”View highlighted excerpt for this quoteNot applicable
REM sleep, %TST: atomoxetine 75 mg“17.8 (13.7–19.0)”View highlighted excerpt for this quote“6.8 (3.5–11.3)”View highlighted excerpt for this quote“−9.32 (−11.14 to −7.50)”View highlighted excerpt for this quote
REM sleep, %TST: AD109 2.5/75 mg“18.6 (14.3–23.0)”View highlighted excerpt for this quote“7.5 (3.7–12.7)”View highlighted excerpt for this quote“−9.74 (−11.78 to −7.69)”View highlighted excerpt for this quote
REM sleep, %TST: AD109 5/75 mg“17.3 (13.5–20.1)”View highlighted excerpt for this quote“5.6 (2.5–10.2)”View highlighted excerpt for this quote“−10.79 (−12.79 to −8.78)”View highlighted excerpt for this quote
WASO, min: placebo“65.1 (41.5–97.8)”View highlighted excerpt for this quote“58.9 (44.5–101.8)”View highlighted excerpt for this quoteNot applicable
WASO, min: atomoxetine 75 mg“70.1 (44.3–98.8)”View highlighted excerpt for this quote“92.9 (61–124.3)”View highlighted excerpt for this quote“20.32 (8.07 to 32.58)”View highlighted excerpt for this quote
WASO, min: AD109 2.5/75 mg“75.6 (56.8–104.3)”View highlighted excerpt for this quote“78.9 (56.8–98.3)”View highlighted excerpt for this quote“0.11 (−13.69 to 13.91)”View highlighted excerpt for this quote
WASO, min: AD109 5/75 mg“73.3 (43.3–93.5)”View highlighted excerpt for this quote“77.0 (48.3–106.3)”View highlighted excerpt for this quote“8.21 (−5.37 to 21.79)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Patient-reported outcomes, placebo-adjusted change from baseline
OutcomeAtomoxetine 75 mgAD109 2.5/75 mgAD109 5/75 mg
PROMIS fatigue, adjusted T-score“−0.07 (−2.93 to 2.79)”View highlighted excerpt for this quote“−3.56 (−6.77 to −0.35)”View highlighted excerpt for this quote“0.10 (−3.02 to 3.21)”View highlighted excerpt for this quote
PROMIS sleep impairment, adjusted T-score“−0.02 (−3.28 to 3.24)”View highlighted excerpt for this quote“−1.99 (−5.67 to 1.69)”View highlighted excerpt for this quote“−0.35 (−3.91 to 3.21)”View highlighted excerpt for this quote
PROMIS sleep disturbance, adjusted T-score“2.40 (−0.07 to 4.87)”View highlighted excerpt for this quote“1.12 (−1.66 to 3.89)”View highlighted excerpt for this quote“0.21 (−2.48 to 2.90)”View highlighted excerpt for this quote
Modified short SAQLI“0.54 (−4.29 to 5.37)”View highlighted excerpt for this quote“−2.28 (−7.73 to 3.17)”View highlighted excerpt for this quote“2.02 (−3.25 to 7.29)”View highlighted excerpt for this quote
ESS score“0.30 (−1.15 to 1.74)”View highlighted excerpt for this quote“−0.23 (−1.85 to 1.39)”View highlighted excerpt for this quote“0.64 (−0.94 to 2.22)”View highlighted excerpt for this quote
PGI-S“−0.25 (−0.73 to 0.23)”View highlighted excerpt for this quote“−0.16 (−0.72 to 0.41)”View highlighted excerpt for this quote“−0.19 (−0.74 to 0.36)”View highlighted excerpt for this quote
QQ“0.44 (−1.2 to 2.12)”View highlighted excerpt for this quote“−0.26 (−2.14 to 1.63)”View highlighted excerpt for this quote“−1.01 (−2.85 to 0.83)”View highlighted excerpt for this quote
Safety results
Most common adverse events (at least three participants in any group)
Adverse eventPlacebo (n = 63)Atomoxetine 75 mg (n = 63)AD109 2.5/75 mg (n = 42)AD109 5/75 mg (n = 41)
Any adverse event“25 (39.7%)”View highlighted excerpt for this quote“51 (81%)”View highlighted excerpt for this quote“26 (61.9%)”View highlighted excerpt for this quote“32 (78%)”View highlighted excerpt for this quote
Adverse event leading to discontinuation“1 (2%)”View highlighted excerpt for this quote“12 (19%)”View highlighted excerpt for this quote“5 (12%)”View highlighted excerpt for this quote“5 (12%)”View highlighted excerpt for this quote
Dry mouth“3 (5%)”View highlighted excerpt for this quote“17 (27%)”View highlighted excerpt for this quote“10 (24%)”View highlighted excerpt for this quote“24 (59%)”View highlighted excerpt for this quote
Insomnia“2 (3%)”View highlighted excerpt for this quote“23 (37%)”View highlighted excerpt for this quote“11 (26%)”View highlighted excerpt for this quote“9 (22%)”View highlighted excerpt for this quote
Urinary hesitation/flow decrease“0”View highlighted excerpt for this quote“14 (22%)”View highlighted excerpt for this quote“3 (7%)”View highlighted excerpt for this quote“9 (22%)”View highlighted excerpt for this quote
Constipation“2 (3%)”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“5 (12%)”View highlighted excerpt for this quote
Nausea“2 (3%)”View highlighted excerpt for this quote“4 (6%)”View highlighted excerpt for this quote“5 (12%)”View highlighted excerpt for this quote“4 (10%)”View highlighted excerpt for this quote
Decreased appetite“1 (2%)”View highlighted excerpt for this quote“5 (8%)”View highlighted excerpt for this quote“2 (5%)”View highlighted excerpt for this quote“4 (10%)”View highlighted excerpt for this quote
Feeling jittery“1 (2%)”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2 (5%)”View highlighted excerpt for this quote“3 (7%)”View highlighted excerpt for this quote
Somnolence“1 (2%)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (2%)”View highlighted excerpt for this quote“3 (7%)”View highlighted excerpt for this quote
Heart rate and blood pressure versus placebo
Registry serious adverse events
MeasureAD109 75/5mgAD109 75/2.5mgAtomoxetine 75mgPlacebo
Serious adverse events“0/41 (0.00%)”“0/42 (0.00%)”“0/63 (0.00%)”“0/63 (0.00%)”
Study limitations
Summary
  • Design: phase 2 dose-finding trial with 4 weeks of dosing; the authors describe its exploratory nature, and no adjustment for multiple comparisons was made.
  • Population: AHI4 of 10 to 45 on two baseline polysomnograms, ages 18 to 65 (men) or 18 to 75 (women), and BMI up to 38 (men) or 40 (women) kg/m2. Exclusions included other clinically important sleep disorders (the prospectus names a history of insomnia), active cardiac disease, and hypertension requiring more than two drugs. PAP intolerance was not required; prior device users enrolled after 2 weeks without use, and 42.9% to 50.2% of each arm reported CPAP use.
  • Eligibility scoring: eligibility used site scoring, and endpoints used central scoring, which led to inclusion of 29 participants with baseline AHI4 below 10 after central scoring.
  • Primary endpoint differs by source: the publication tests each AD109 dose against placebo, and the registry names the combined AD109 arms against placebo. The registry states the trial was not powered to compare individual doses and that individual dose results should be interpreted descriptively.
  • Missing data: the statistical analysis plan had no prespecified imputation, so efficacy used the modified intention-to-treat population (181 of 211 randomized); the intention-to-treat analysis was post hoc.
  • Discontinuation: study discontinuation due to adverse events was 5 (12%) in each AD109 group, 12 (19%) with atomoxetine alone, and 1 (2%) with placebo.
  • Outcomes: the authors attribute the lack of PRO differences to a placebo effect and mild baseline symptoms, PROs were analyzed in the subset with assessments, and the authors suggest limited REM data during treatment as a possible reason the REM reduction was not significant versus placebo.
  • Reporting: registry enrollment of 294 includes two AD504 arms reported separately, and registry results were first posted on 2026-08-12, after study completion on 2022-08-03.
  • Source discrepancies: the publication states no serious adverse events were reported and also that two events classified as serious led to discontinuation with atomoxetine alone, while the registry lists 0 serious adverse events in every arm. Dry mouth with placebo is 3 (5%) in the publication and 10/63 (15.87%) in the registry. The prospectus gives a start in December 2021, and the registry and publication give November 29, 2021.
  • Sponsor: the prospectus describes MARIPOSA as a trial the company initiated.